LIG1 and cancer: We questioned whether the SL between LIG1 and PARP is translatable to various cancer types, also in keeping with recent CRISPR/Cas9 genome-wide screens in BRCA and OV cell lines treated with PARPi that reported LIG1 among the genes giving sensitivity to the treatment, although this association was not pursued further (45, 46).